@article{196764c51fd54da1babb8382e4d9397b,
title = "Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform",
keywords = "Antineoplastic Agents/therapeutic use, Health Services Accessibility, Humans, Netherlands",
author = "Zeverijn, \{Laurien J.\} and \{van Waalwijk van Doorn-Khosrovani\}, \{Sahar Barjesteh\} and \{van Roy\}, \{Anke A.M.G.Pisters\} and Lonneke Timmers and \{Ly Tran\}, \{T. H.\} and \{de Boer\}, \{Jolanda E.\} and \{de Wit\}, \{Gijsbrecht F.\} and Geurts, \{Birgit S.\} and Hans Gelderblom and Verheul, \{Henk M.W.\} and Nicole Blijlevens and Wymenga, \{A. N.Machteld\} and Eskens, \{Ferry A.L.M.\} and Smit, \{Egbert F.\} and Bloemendal, \{Haiko J.\} and Voest, \{Emile E.\}",
note = "Funding Information: EFS reports grants form AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Bayer, Merck Sharp \& Dphme, Eli Lilly, Daiichi Sankyo, Roche, Novartis, Takeda, Pharmamar; received consulting fees from Eli Lilly; and received payments or honoraria for lectures, presentations, speakers{\textquoteright} bureaus, manuscript writing, or educational events for Boehringer Ingelheim, AstraZeneca, Daiichi Sankyo, and Novartis, all outside the submitted work. EEV reports grants from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis Oncology, GlaxoSmithKline, Merck Sharp \& Dohme, Novartis , Pfizer, Roche, and Sanofi, all outside the submitted work. All other authors declare no competing interests. The DRUG Access Protocol is supported by all participating pharmaceutical companies: Bayer, Roche, and Sanofi. No company had a role in writing of the manuscript or decision to submit it for publication. EEV, HJB, and EFS led the DRUG Access Protocol trial as principal investigators. HG and HMWV functioned as co-principal investigators for the trial. LJZ and SBvWvD-K wrote the manuscript. LJZ, GFdW, and BSG coordinated the trial. SBvWvD-K and AAMGP-vR functioned as representatives on behalf of the health insurance companies during trial design. LT, THLT, and JEdB represented the Dutch National Health Care Institute during trial design. NB, ANMW, FALME, and EFS functioned as representatives of the Dutch Medical Societies for Oncology, Pulmonology and Haematology during trial design. LJZ and SBvWvD-K contributed equally as first authors. ",
year = "2022",
month = feb,
doi = "10.1016/S1470-2045(21)00707-5",
language = "English",
volume = "23",
pages = "198--201",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Limited",
number = "2",
}